Endorse review of the “Myoblast Therapy Technology " by CMDA experts held in Beijing

2013-03-28 13:22

     February 28th, 2013, “Myoblast Therapy Technology" was reviewed by experts assembled by the Chinese Medical Doctor Association(CMDA) in Beijing. Professor Cai Zhongjun, Consultant of the CMDA, attended the conference. All the staff of the Career Development Ministry and nearly 20 experts from major hospitals nationwide attended the conference. The conference was presided by the Director of the Institute of Immunology in Huazhong University of Science and Technology Tongji Medical College, Professor Gong Feili, and the Director of theCareer Development Ministry in CMDA, Mr. Liu Qilin.

     The project leader and creator of the Myoblast Therapy Technology, Professor Peter K. Law, comprehensively introduced to the experts the basic research and the progress on clinical trials of the technology. Myoblasts are precursor cells of muscle tissue, derived from mesodermal myoblasts. They have the ability to self-renew and promote regeneration of muscle fiber, and above all things is that they have the function of natural fusion. When implanted into patients, myoblasts can be divided into normal muscle cells, thus restoring the physiological function of damaged muscle tissue or organ. Two grams of skeletal muscle were collected, followed by separation and culture. The muscle can amplify 50 billion myoblasts of high-purity and high vitality (the average purity exceeded 99%). The clinical trials carried out in foreign countries proved the technology reliable and secure.

  Professor Cai Zhongjun pointed out in the concluding remarks that the experts have carefully reviewed the scientificity, innovation, progression, clinical efficacy, safety and the future development of the therapy technology and the conclusion shows the opinions of the experts. Experts attending the conference believe that Myoblast Therapy Technology has a wide array of applications. For example, in the treatment of neuromuscular disease, its efficacy is superior to existing therapies. In the treatment of ischemic heart disease it has unique advantages and can be used in conjunction with other therapies thus significantly improve the curative effect. Promotion and application of the technology is expected to yield the great social and economic benefits.

Experts attending the conference suggested to promote the clinical trials as soon as possible and that in the preliminary trials, myoblasts should be drawn from the muscles of immediate family members or through autologous extraction. They suggested to cooperate with qualified domestic medical institutions and strictly chose the indications (neuromuscular atrophy, ischemic heart disease, etc.) to carry out the clinical trials. After ensuring its exact effects, it can be promoted for further application. The experts also suggested to rely on CAMD to promote the application and approve of the technology.

Finally, the experts unanimously concurred that the project conforms to the requirements of “Cell Transplantation Therapy Technology” as listed in the Third-Category Medical Technology and ready to recommend the technology to the department in charge of clinical trial application. Professor Gong Feili read the experts’ judgment on Myoblast Therapy Technology on the spot.

 The spot of the conference

Group photo of the experts attending the conference

See the news on the website of the Chinese Medical Doctor Association:

    http://wwwNaNda.gov.cn/xiehuixiangmu/shiyefazhanbu/bumendongtai/2013-03-04/11778.html